Genetic
1934, published clinical and biochemical description by Ivar Asbjørn Følling, Norway
Phenylketonuria was an entirely unknown condition until the early twentieth century, when a Norwegian physician's careful observation of two affected children set in motion a chain of biochemical discoveries that would reshape the understanding of inherited metabolic disease. For most of human history, the intellectual disabilities associated with untreated cases were attributed to birth injuries, divine punishment, or hereditary weakness of the mind, with no recognition of any underlying chemical mechanism. The unraveling of its biochemical basis became one of the founding stories of the discipline of inborn errors of metabolism.
Historical Narrative
Before the twentieth century, no physician in any tradition possessed the conceptual framework necessary to identify phenylketonuria as a distinct condition. Individuals with the severe intellectual and developmental consequences of untreated cases were grouped indiscriminately with others exhibiting cognitive differences, and explanations ranged from supernatural causes in ancient and medieval societies to hereditary degeneracy theories that gained currency in the nineteenth century. The specific combination of features that characterized the condition went unrecognized as a coherent clinical entity.
The history of phenylketonuria as an identified medical condition begins definitively in 1934 with the work of Ivar Asbjørn Følling, a Norwegian physician and biochemist. A mother of two children with intellectual disabilities brought them to Følling's attention, having noticed an unusual musty odor associated with them. Følling's methodical chemical investigation of their urine revealed the presence of phenylpyruvic acid, a substance not normally found in significant quantities in human urine. He subsequently identified the same compound in additional affected individuals, establishing for the first time that a specific biochemical abnormality was shared among a group of patients with similar cognitive and physical characteristics.
Folling published his findings in 1934 under the title describing oligophrenia phenylpyruvica, introducing the condition to the international medical community. His work was immediately recognized as remarkable because it demonstrated that a specific chemical aberration in the body could produce profound effects on intellectual development, a connection that had never been established with such clarity for any comparable condition. His discovery built upon the earlier theoretical framework established by Archibald Garrod, the British physician who had proposed around 1902 the concept of inborn errors of metabolism, arguing that certain hereditary conditions represented blocks in normal chemical pathways rather than infectious or purely structural diseases.
Throughout the late 1930s and 1940s, researchers across Europe and North America worked to characterize the biochemical pathway involved. George Jervis, working in the United States, made critical advances in the 1940s and early 1950s by demonstrating that the liver enzyme responsible for converting phenylalanine to tyrosine was deficient or absent in affected individuals, pinpointing the precise metabolic block that Følling's original discovery had implied. Jervis's work established the enzymatic basis of the condition and confirmed that phenylalanine accumulated in the blood and tissues when this conversion could not proceed normally.
A transformative moment in the condition's history arrived in the early 1950s when Horst Bickel, a German physician working in Birmingham, England, collaborated with colleagues to develop a phenylalanine-restricted dietary formula and demonstrated in a single well-documented case that altering the diet of an affected child produced measurable improvements in biochemical markers and apparent cognitive responsiveness. Published in 1953, this work opened the possibility that the consequences of the metabolic block might be ameliorated through dietary management, shifting phenylketonuria from a condition of inevitable outcome to one that researchers believed might be modifiable.
The final major historical turning point came with the development of the Guthrie bacterial inhibition assay by Robert Guthrie in the early 1960s. Guthrie, whose own family had been affected by intellectual disability, devised a simple and inexpensive blood test capable of detecting elevated phenylalanine levels in newborns before severe developmental consequences had occurred. His test made population-wide newborn screening a practical possibility, fundamentally altering the public health approach to this and subsequently many other inherited metabolic conditions.
Key Historical Figures
Historical narrative only — this page describes how Phenylketonuria was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.